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OBJECTIVE — Evaluation of the time required until a change in the basal insulin infusion
rate with an insulin pump induces subsequent changes in the metabolic effect.
RESEARCH DESIGN AND METHODS — In this euglycemic glucose clamp study, 10
male subjects with type 1 diabetes received three different subcutaneous insulin infusion rates
(0.5, 1.0, and 2.0 units/h; for 4 h each) of insulin lispro (IL) with insulin pumps.
RESULTS — An increase in insulinemia occurred within 15–30 min after changing the infu-
sion rate. While the serum IL levels reached a steady state at the end of the infusion period, the
glucose infusion rates did not always reach steady-state levels with the higher infusion rates.
However, an increase in the glucose consumption occurred within 30–60 min after switching
the infusion rate.
CONCLUSIONS — Severalhoursarerequireduntilanewsteadystateinthemetaboliceffect
is achieved after a signiﬁcant change in basal insulin infusion.
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D
epending on the therapeutic strat-
egy, patients on continuous subcu-
taneous insulin infusion (CSII) are
often instructed to vary their basal rates
over 24 h in a speciﬁc pattern. Therefore,
changesininsulininfusionareinitiatedat
hourly intervals in many patients. Previ-
ous studies indicate that it takes 2–3 h
until a change of 0.5–1 units of regular
insulin in basal insulin infusion rates
leads to a relevant change in insulin ab-
sorption using regular insulin (1–3). The
respective change in serum insulin levels
hasnotbeeninvestigatedsimultaneously.
The aim of this study was to evaluate how
rapidly changes in basal insulin infusion
rates are reﬂected in circulating insulin
levels and the respective metabolic effect
when infusing a rapid-acting insulin
analog.
RESEARCH DESIGN AND
METHODS— Thiswasanopen-label,
randomized, monocenter euglycemic
glucose clamp study with 2 identical
study days except for the insulin pumps
used. Ten male patients with type 1 dia-
betes were enrolled (age 41  9 years;
BMI 25.2  2.4 kg/m
2; A1C 7.1  0.4%;
fouronCSII;totaldailyinsulindose57
13 IU, 0.68  0.12 IU/kg body wt). This
study was performed according to good
clinical practice guidelines, including in-
formed consent.
Onbothstudydays,identicalandsta-
ble glycemia (blood glucose target 6.0
mmol/l) and insulinemia (basal intrave-
nous[IV]infusionofregularhumaninsu-
lin [RHI] 0.2 mU   kg
1   min
1) were
established overnight by automated glu-
cose clamps. On both study mornings,
subcutaneous (SC) infusions of insulin
lispro (IL) with the commonly used insu-
lin pumps Paradigm 522 (MiniMed,
Northridge, CA) and Accu-Chek Spirit
(Roche Diagnostics, Mannheim, Ger-
many) were established. Use of different
insulin formulations for IV and SC infu-
sions allowed differentiation of insulin
applied via the two infusion routes. After
a baseline infusion rate (0.1 units/h for
4h),thefollowinginfusionrateswereap-
plied (units/h for 4 h each): 0.5, 1.0, and
2.0. The same infusion protocol was em-
ployed on both study days.
One of the two radioimmunoassays
used measured total insulin levels (IL and
RHI); the other measured RHI only. Se-
rum IL levels were calculated from the
difference between the measurements.
The time required until glucose infusion
rates (GIRs) reached a new steady-state
level was evaluated during each of the
three infusion periods. Free fatty acid
(FFA) levels were measured in the blood
samples as a secondary sensitive measure
forinsulinactionwithastandardmethod.
The summary measures obtained
were compared by means of a paired Stu-
dent’s t test. Because no signiﬁcant differ-
ences between the 2 study days were
observed,thecombineddataofbothdays
were presented.
RESULTS— Mean blood glucose was
keptconstantthroughouttheinfusionpe-
riods (6.0  0.1 mmol/l; coefﬁcient of
variation 2%) (Fig. 1A). IV infusion of
RHI throughout the experiments estab-
lished stable serum insulin levels (79  5
pmol/l) (Fig. 1B). Serum IL levels in-
creased during the 0.5 units/h infusion
period from 21  19 to 28  16 pmol/l
(meansSD;P0.01vs.baseline)(Fig.
1C). With an infusion rate of 1.0 units/h,
nearly a doubling of the IL levels was ob-
served (to 54  20 pmol/l; P  0.001 vs.
end of 0.5 units/h). An increase in insu-
linemia occurred within 15–30 min after
switching the infusion rate. With an infu-
sion rate of 2.0 units/h, another twofold
increase in insulinemia took place (to
10727pmol/l;P0.001vs.endof1.0
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state level in the last 120 min within the
0.5 and 1.0 units/h infusion period. No
steadystatewasachievedwithaninfusion
rate of 2.0 units/h, but there still was an
increase after 4 h.
GIR showed no signiﬁcant increase
during the infusion of 0.5 units/h (from
0.11.0to0.32.5mg kg
1 min
1;
NS); however, with a doubling of the in-
fusionrateto1.0units/h(to1.72.5mg
  kg
1   min
1; P  0.001) and again to
2.0 units/h (to 3.8  3.5 mg   kg
1  
min
1; P  0.02), such an increase was
registered (Fig. 1D). This increase oc-
curred within 30–60 min after switching
the infusion rate. GIR reached a steady
stateinthelast120minofthe0.5and1.0
units/h infusion period but not with the
infusion rate of 2.0 units/h. FFA levels re-
mained stable during the infusion period
with 0.5 units/h (Fig. 1E). However, the
further increase in insulinemia sup-
pressed FFA levels by 65%.
CONCLUSIONS — This study indi-
cates that it takes 2.5–4 h until a consid-
erable change in basal infusion rate (0.5–
1.0 units/h) leads to a new steady-state
level in the induced metabolic effect even
if a rapid-acting insulin analog is infused.
Research on peak action of insulin bo-
luses revealed that it takes 60 min until
insulinand100minuntilGIRreachmax-
imum levels (4). Similar changes of basal
insulin infusion have also been evaluated
employingcessationofinsulindelivery.It
hasbeendisclosedthatwithIL,metabolic
changes occurred within 1 h after termi-
nationofinsulininfusionandwereclearly
demonstrated after 3 h (5–7).
Indailypractice,thehourlybasalrate
pattern most often is not varied to this
extent from hour to hour but is adjusted
in smaller steps as shown for instance in
children and adolescents (8). The differ-
entbasalratesinthisstudywerechosento
demonstrate substantial changes in insu-
linemia, glucose consumption, and FFA
levels. However, a longer evaluation pe-
riod of 5–6 h would have been more ap-
propriatetodemonstratethatnewsteady-
state levels were reached.
Considering the observed delay after
a signiﬁcant change in the basal rate, the
time gap before achieving a new stable
metabolic effect should be taken into ac-
count when modifying the basal rate.
There is a good body of clinical experi-
enceindicatingthatindividualbasalinsu-
linadjustmentviaCSIIisthebestmanner
Figure 1—Means SE glycemia (A), serum human insulin (B), serum IL (C), GIRs (D; with
baseline correction), and FFA levels (E) measured in 10 male subjects with type 1 diabetes with
three different basal SC insulin infusion rates (0.5, 1.0, and 2.0 units/h), in addition to a baseline
IV infusion of RHI (0.2 mU   kg
1   min
1).
Metabolic effects of changing basal rates
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data presented here indicate that the op-
tions of modern insulin pumps need ad-
equate coordination and ﬁne-tuning with
the metabolic effect. The observed delay
also has to be considered when stopping
the insulin infusion to avoid or to attenu-
ate the development of a hypoglycemic
event (5,7).
In summary, signiﬁcant changes in
basal insulin infusion rates with CSII
might require several hours until a new
stable metabolic effect level is reached.
This topic should be systematically eval-
uated in greater detail within clinical
trials.
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